PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: In Press PR Ltd

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

New Range of Recombinant Fab Monoclonal Antibodies Launched at AACC 2013 - The AACC Conference and Expo sees the launch of an innovative new range of recombinant Fab monoclonal antibodies from BBI Solutions - AACC.org / BBISolutions.com
New Range of Recombinant Fab Monoclonal Antibodies Launched at AACC 2013

 

NewswireToday - /newswire/ - Cardiff, Wales, United Kingdom, 2013/07/16 - The AACC Conference and Expo sees the launch of an innovative new range of recombinant Fab monoclonal antibodies from BBI Solutions - AACC.org / BBISolutions.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

BBI Solutions, a world leader in immunoassay development and contract manufacturing, will launch its unique range of Recombinant Fab Monoclonal Antibodies on booth #3363 at the American Association for Clinical Chemistry’s (AACC) Annual Meeting and Clinical Lab Expo, on July 28-August 31, 2013, in Houston, Texas. These matched antibodies pairs, developed using proprietary phage display selection and the Luminex platform, exhibit sub-nanomolar affinities, exceptional sensitivity, and provide assay developers with clinically relevant performance characteristics to 34 biomarkers, with more in development.

The new Recombinant Fab Mouse Monoclonal Antibodies from BBI Solutions exhibit significant advantages over standard mouse monoclonal antibodies. From the screening process to testing in patient samples to ensure clinical significance, BBI Solutions’ methodology ensures that companies developing new assays have the most sensitive and reliable antibodies available in the market.

Because these new antibodies are grown in and purified from E. coli cultures, production is much quicker and more reliable than standard cell culture techniques, and large scale production is not an issue.

In regard to the new range, Dr. James Steggles, Commercial Manager at BBI Solutions, says,“Here at BBI Solutions it is our aim to ensure that we supply the market with antibodies that have world-class performance and give our customers significant advantages over their competitors. Each antibody pair is the best from a billion clones screened and 4500 matched pairs tested. By using this new range of monoclonal antibodies, they can produce clinical assays that are more sensitive and reliable than their competitors, as well as more cost-effective due to reduced R&D costs.”

BBI Solutions scientists (bbisolutions.com) will be at the AACC Conference to discuss the development of new products and any specific requirements customers may have.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: In Press PR Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


New Range of Recombinant Fab Monoclonal Antibodies Launched at AACC 2013

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Julie Hart - BBISolutions.com 
+44(0)29 2074 7232 info[.]bbisolutions.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any In Press PR Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From In Press PR Ltd / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

PleurX™ Catheter System Receives FDA 510(k) Clearance for Specific Non-Malignant Recurrent Pleural Effusions
First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
Sugar Element of Keratan Sulfate Halts the Progress of Emphysema Finds RIKEN
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
MDxHealth Announces AceCGT Life Science Limited as the Exclusive Distributor for SelectMDx in Hong Kong and Macao China
Pulse Certified As A Level Four Multichannel Content Agency by Veeva Systems
BD Launches Advanced Prefillable Syringe for Higher Volume Injection of Biologics
Sartorius Announces Expansion of Sartorius Stedim Cellca
Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
BD Integrating Technology, Expertise and Services to Provide Comprehensive Medication Management

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  NAKIVO, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)